Oncology & Cancer

Cancer risk declines in old age: New research helps explain why

When it comes to cancer, aging is a double-edged sword, researchers are increasingly learning. Age is considered the most important risk factor for cancer. That's because genetic mutations build up in cells over years and ...

Other

Roche in $1.5 bn deal to buy Poseida Therapeutics

Swiss pharmaceutical giant Roche said on Tuesday it agreed to buy US biopharma firm Poseida Therapeutics for $1.5 billion (1.4 billion euros)—but Roche shares dipped over a disappointing study on a key lung cancer treatment.

page 2 from 40